Table 1.
Clinicopathological characteristics of primary surgical breast tumor specimens
| Characteristics | Total patients (n = 25) | HER2+ (n = 14) | TN (n = 11) |
|---|---|---|---|
| Age, years | |||
| Median (range) | 48 (28–64) | 46 (28–61) | 49 (40–63) |
| T | |||
| 1 | 7 (28) | 4 (29) | 3 (27) |
| 2 | 12 (48) | 8 (57) | 3 (27) |
| 3 | 2 (8) | 1 (7) | 1 (9) |
| 4 | 2 (8) | 0 (0) | 2 (18) |
| Unknown | 2 (8) | 1 (7) | 2 (18) |
| N | |||
| 0 | 14 (56) | 8 (57) | 6 (55) |
| 1 | 6 (24) | 5 (36) | 1 (9) |
| 2 | 0 (0) | 0 (0) | 0 (0) |
| 3 | 3 (12) | 1 (7) | 2 (18) |
| Unknown | 2 (8) | 0 (0) | 2 (18) |
| Stage | |||
| 1 | 5 (20) | 2 (14) | 3 (27) |
| 2 | 13 (52) | 10 (71) | 3 (27) |
| 3 | 4 (16) | 1 (7) | 3 (27) |
| 4 | 0 (0) | 0 (0) | 0 (0) |
| Unknown | 3 (12) | 1 (7) | 2 (18) |
| Histological grade | |||
| 1 | 5 (20) | 2 (14) | 3 (27) |
| 2 | 13 (52) | 8 (57) | 5 (45) |
| 3 | 7 (28) | 4 (29) | 3 (27) |
| ER | |||
| Positive | 11 (44) | 11 (79) | 0 (0) |
| Negative | 14 (56) | 3 (21) | 11 (100) |
| Chemotherapy | |||
| No | 5 (20) | 4 (29) | 1 (9) |
| Neoadjuvant | 6 (24) | 3 (21) | 3 (27) |
| Adjuvant | 13 (52) | 7 (50) | 6 (55) |
| Unknown | 1 (4) | 0 (0) | 1 (9) |
| Trastuzumab | |||
| No | 21 (84) | 12 (86) | 9 (82) |
| Yes | 3 (12) | 2 (14) | 1 (9) |
| Unknown | 1 (4) | 0 (0) | 1 (9) |
| Endocrine therapy | |||
| No | 11 (44) | 4 (29) | 7 (64) |
| Yes | 13 (52) | 10 (71) | 3 (27) |
| Unknown | 1 (4) | 0 (0) | 1 (9) |
| Radiotherapy | |||
| No | 16 (64) | 10 (71) | 6 (55) |
| Adjuvant | 8 (32) | 4 (29) | 4 (36) |
| Unknown | 1 (4) | 0 (0) | 1 (9) |
| Alive at last follow‐up | |||
| No | 10 (40) | 6 (43) | 4 (36) |
| Yes | 15 (60) | 8 (57) | 7 (64) |
Data are shown as n (%) unless otherwise indicated. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative.